Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Recs

0
Player Avatar cayamax (< 20) Submitted: 9/11/2009 11:09:20 AM : Outperform Start Price: $19.27 EBS Score: -55.11

Sadly, bioterrorism and biowarfare will be a threat for quite awhile.

Featured Broker Partners


Advertisement